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Enteroviral Encephalitis in a Child With CNS Relapse of
Burkitt Leukemia Treated With Rituximab
Najma Shaheen, MD and Francis Mussai, MD, DPhil
Summary: A boy with central nervous system relapse of Burkitt
leukemia developed fever and neurological symptoms and cognitive
impairment. He had received multi-drug chemotherapy including
rituximab. Enterovirus (EV) was detected in cerebrospinal ﬂuid by
polymerase chain reaction, and magnetic resonance imaging ﬁnd-
ings were consistent with viral infection. The patient was treated
with intravenous immunoglobulin and within 1 month cleared his
EV. Rituximab can cause a profound B-cell deﬁciency predisposing
patients to infections including EV encephalitis. This is the ﬁrst
report of enteroviral encephalitis in a child undergoing treatment for
lymphoma with rituximab and suggests the need to watch for this
complication of therapy.
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BACKGROUND
Rituximab is a chimeric anti-CD20 monoclonal anti-
body and increasingly being used for the treatment of B-cell
lymphoma, posttransplantation B-cell lymphoproliferative
disorders and autoimmune cytopenia.1,2 It has signiﬁcantly
improved the outcome of high-risk B-cell non-Hodgkin
lymphoma in children and adolescents and is being incor-
porated alongside standard chemotherapeutics in the treat-
ment of high-risk disease.3
Adult patients receiving rituximab have a modest
increased risk of infections secondary to decreased B cell
number and function.4,5 Here we report the occurrence of
enterovirus (EV) encephalitis in a child with relapsed Burkitt
leukemia following rituximab therapy.
OBSERVATIONS
A 5-year-old boy presented with 4-week history of back
pain, progressive pallor, and pancytopenia on peripheral
blood examination. Bone marrow showed 97% inﬁltration
with blasts. Immunophenotyping of blasts identiﬁed CD10,
CD19, and CD22 more than 99%, surface immunoglobulin
(Ig) M 99%, lambda 98%,cytoplasmic mu 96%, kappa 5%,
tdt 1%, and CD34< 1% expression. Cytogenetics conﬁrmed
IGH-MYC rearrangements by interphase ﬂuorescence
in situ hybridization. Blasts were also documented in the
cerebrospinal ﬂuid (CSF). No other cells were seen. At
diagnosis, computed tomography and magnetic resonance
imaging reported no systemic lymphoma masses. The
patient was treated according to Inter-B-NHL 2010 Proto-
col, Group C3. The CSF was cleared of blasts after the ﬁrst
intrathecal chemotherapy.
Unusually from day 8 the CSF showed an increased
white cell count (15 WBC/mm3) with 26% lymphocytes, 62%
neutrophils, and 12% monocytoid cells but no morphologic
evidence of blasts on cytospin. Peripheral blood counts on
day 8 revealed a hemoglobin 103 g/L, white blood cell count
1.1×109/L, neutrophil count 0.7×109/L, lymphocyte count
0.3×109/L, and platelets 91×109/L. Post R-COPADM1, the
patient developed persistent fever unresponsive to anti-
bacterial and antifungal treatment, with negative blood
cultures and no localizing signs of infection on cross-sec-
tional imaging. He received 2 doses of rituximab but the
remaining drugs in COPDAM2 were delayed due to his
clinical condition. Repeat CSF examination identiﬁed an
isolated CNS relapse (on day 33 from commencement of the
treatment). Immunophenotyping reported a 37% malignant
population with CD22 and lambda expression > 96% and
surface IgM 99%. No lymphoma masses were identiﬁed on
cross-sectional imaging of the brain and spine. The bone
marrow remained in remission. Treatment with rituximab,
ifosfamide, carboplatin, etoposide, and dexamethasone (R-
ICED) was commenced. CSF from same date detected EV
by polymerase chain reaction but was reported negative for
cytomegalovirus, herpes simplex virus 1 and 2, human
herpes virus 6, Epstein-Barr virus, human parechovirus, and
varicella zoster virus. In view of enteroviral infection
intravenous immunoglobulin (IVIg) (0.5 g/kg/mo) was
commenced. IgG levels at the time of leukemia diagnosis
were in the normal range 5.17 g/L (4.9 to 16.1 g/L). The CSF
was cleared of blasts after 2 intrathecal chemotherapy doses
and prophylactic triple ITs were continued. However brfore
second cycle of R-ICED, the patient again developed fever,
recurrent focal seizures and a signiﬁcant impairment of
consciousness.
An electroencephalogram reported mild slow ence-
pahlo-pathic background with no epileptic focus. Meningitic
dose of IV meropenem, acyclovir and antiepileptic (levetir-
acetam) were commenced. Lumber puncture showed pleo-
cytosis including neutrophils, lymphocytes, monocytes, and
elevated protein (maximum 1.2 g/L). There was no mor-
phologic or immunophenotypic evidence of Burkitt blasts.
EV was again reconﬁrmed in the CSF by polymerase chain
reaction and all other microbiological cultures remained
negative on multiple occasions. One week later he had
another episode of recurrent seizures followed by pro-
gressive alteration in cognitive functions associated with
aphasia. On examination he had globally increased tone,
brisk reﬂexes, decreased power, and upgoing planter. No
focal neurological signs were noticed. Magnetic resonance
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imaging of the head identiﬁed symmetrically high signals of
bilateral basal ganglia, brain stem and around fourth ventricle,
most consistent with viral encephalitis (Fig. 1). Alternative
diagnoses including chemotherapy induced neurotoxicity and
vitamin B6 deﬁciency (B6 level was 247 higher than normal
range) were considered too.
The patient continued to be treated with weekly doses
of IVIgs (0.5 g/kg). A repeat lumber puncture 1 month after
the onset of neurological symptoms conﬁrmed EV clearance
of CSF. Unfortunately, the patient has continued to have
signiﬁcant neurological sequelae including impaired cogni-
tion, aphasia and movement disorders, despite remaining in
leukemic remission.
CONCLUSIONS
Rituximab is recognized as standard agent in the treat-
ment of pediatric high-risk B-cell lymphoma. On binding to
CD20 it induces apoptosis and antibody dependent cellular
cytotoxicity which leads to reduction in malignant blasts but
also a rapid and long lasting depletion of circulating B cells. In
the majority of patients this leads to no signiﬁcant morbidities,
and as such rituximab is seen as having a relatively good
safety proﬁle compared with standard chemotherapy. How-
ever in adults, several infectious side effects including hepatitis
B reactivation, pneumocystis jirovecii pneumonia, progressive
multifocal encephalopathy and EV meningoencephalitis have
been reported.6–10
In the literature, 11 cases of EV meningoencephalitis
are reported following rituximab therapy. In all rituximab
was administered alongside immunosuppressive or cytotoxic
drugs. Six patients were diagnosed with diffuse large B-cell
lymphoma, 4 with follicular lymphoma and 1 with pro-
gressive marginal zone lymphoma. Among these only 1
patient is of pediatric age group diagnosed with severe idi-
opathic thrombocytopenic purpura. Because of the poor
response he had multiple treatment modalities including 2
courses of rituximab infusions 6 months apart. Eleven
months after the second course of rituximab infusions he
presented with neurological impairment secondary to EV
encephalitis. In all these patients the time interval between
treatment with rituximab and neurological symptoms was
variable (concurrent to 11 mo after completion) and patients
died from EV meningoencephalitis, another infection or had
only partial neurological improvement.6,11–18
EV are routinely neurotropic viruses. These viruses have
the ability to enter into multiple CNS cell types including
astrocytes, oligodendrocytes, microglial cells, neural progeni-
tor, and stem cells thus enhancing their ability to persist and
disseminate. Neurons may be more susceptible to EV infec-
tion due to the availability of speciﬁc internal ribosomal entry
site trans-acting factors. The viral genome includes several cis-
acting RNA which plays an important role in replication and/
or translation. These viruses are highly cytolytic due to their
ability to completely impair the host cells’ translational
machinery, thereby causing cytopathic effects. Viral protein
2B is a highly efﬁcient viroporin which can permeablize the
host cell membrane, as well as those of nearby cells. In
addition EVs subvert the autophagic machinery to beneﬁt
their assembly, maturation and exit from host. EVs induce
both antiapoptotic (3A and 2B proteins) and proapoptotic
effects (VP2, 2A, and 3C proteins) on the host cell.2 Neu-
tralizing antibodies are thought to play a signiﬁcant role in
limiting EV infections. Hypogamma-globulinemic conditions
increases the susceptibility to EV infections of CNS. Enter-
oviral genetic material can remain latent for a long time and
in the presence of hypogammaglobuinemia may be reac-
tivated and spread unchecked.19
Only few cases of rituximab associated EV encephalitis
in adults with B-cell lymphoma have been reported, most
with a grim outcome. The use of IvIg since the early 1980s
has virtually eradicated EV meningoencephalitis in patients
with congenital agammaglobulinemias. To our knowledge,
this is the ﬁrst report of EV encephalitis in a child with B-cell
lymphoma. Our case illustrates that clinical symptoms and
radiological abnormalities for EV encephalitis are non spe-
ciﬁc, especially in immunocompromised patients, leading to
diagnostic difﬁculties. During early presentation, detection
of viral RNA in the CSF may be falsely negative, due to low
viral load. In this case the immunosuppressive effect of
myelosuppressive chemotherapy may also have contributed
to slow viral clearance.
FIGURE 1. Magnetic resonance imaging showing T2 axial section (A) and FLAIR (B) axial sequences of the brain of 5-year-old boy with
enterovirus encephalitis. Imaging reveal symmetrical high signal of the basal ganglia, brain stem and around fourth ventricle.
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Current treatment strategies involve the use of weekly
immunoglobulins. The IVIg-based therapy, in addition to
other inﬂammatory mechanisms might neutralize the cir-
culating infectious virus within the host by passive
immunization.20 IVIG has also been administered
intraventricularly, via Ommaya reservoir, with mixed clin-
ical responses.21 Although antiviral therapies like pleconaril
and ribavirin have been shown to have some preclinical
activity none are licensed for this indication. Ribavirin is a
nucleoside analog and has been shown to inhibit the repli-
cation of a variety of EVs. Ribavirin acts by generating a
highly, variable, noninfectious quasispecies and causing
lethal mutagenesis. However, there are conﬂicting reports
on the ability of ribavirin to cross the blood-brain barrier.22
In addition, resistance against ribavirin is also reported.
Pleconaril is another antiviral agent, that has the ability to
cross the blood-brain barrier and remain within the CNS at
concentrations that inhibit EV replication.23 Pleconaril acts
by inhibiting both viral attachment to the cognate receptor
and uncoating of the nucleocapsid during replication.
Studies have demonstrated that Pleconaril may be a val-
uable compound in the treatment of some EV infections of
the CNS but resistance is also documented in some reports.
Other nonapproaches such as rupintrivir and 17-AAG are
undergoing preclinical testing.24 With the increasing use of
rituximab in children, a high index of suspicion is required
in the development of unusual fevers or neurological signs.
The development of a screening strategy for EV infections,
sequential measurement of B cell and IgG concentrations
and use of prophylactic Immunoglobulin in children who
are receiving rituximab should be considered.
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